Masked divergence in cancer mortality following COVID-19 disruption
Cancer Epidemiology · 2026-08 · 103 · 103133
DOI: 10.1016/j.canep.2026.103133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Epidemiology, 2026-08. Verfasst von Mohammad Ahsen Soomro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, The Wright Center for Graduate Medical Education, Scranton, PA, USA. Hauptthemen laut MEDLINE: COVID-19, Neoplasms. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: While overall cancer mortality in the United States has declined steadily for decades, systemic healthcare disruptions during the COVID-19 pandemic-including delays in screening, diagnosis, and treatment-may have created heterogeneous impacts across different malignancy types that are not visible in aggregate data. OBJECTIVE: To determine whether site-specific cancer mortality during the COVID-19 pandemic (2020-2023) deviated from expected trajectories based on established pre-pandemic trends. METHODS: This population-based analysis utilized U.S. National Vital Statistics System data from 2003 through 2023. Age-standardized mortality rates (AASRs) were calculated for specific cancer sites and modeled using log-linear regression over the baseline period (2003-2019). These models were used to project counterfactual expected mortality for the pandemic period (2020-2023). Excess mortality was defined as the percent difference between observed and projected AASRs, with significance determined via bootstrap simulation and false discovery rate correction. RESULTS: Overall cancer mortality remained closely aligned with pre-pandemic declining projections. However, site-specific analysis revealed significant divergence. Positive excess mortality was observed for Hodgkin lymphoma (mean +9.5%; 95% CI, 2.7-17.2%) and prostate cancer (mean +7.9%; 95% CI, 2.8-13.2%). Additionally, mortality attributed to ill-defined malignant sites (+15.2%) and unspecified sites (+8.5%) increased significantly. Conversely, liver and intrahepatic bile duct cancers demonstrated mortality below expected levels (mean -15.5%; 95% CI, -19.5% to -11.3%). Most positive deviations peaked in 2022, suggesting a delayed effect of disrupted diagnostic and clinical pathways. CONCLUSION: Aggregate cancer mortality trends during the pandemic masked significant, disease-specific divergences. The observed excess mortality in certain highly curable or screen-detected malignancies may reflect differential vulnerability to disruptions in screening, diagnosis, treatment access, or cause-of-death attribution. These findings highlight the need for site-specific surveillance to identify long-term consequences of systemic strain and to inform targeted recovery efforts in oncologic care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, The Wright Center for Graduate Medical Education, Scranton, PA, USA.
- Lake Erie College of Osteopathic Medicine, Erie, PA, USA. Electronic address: AVarghese79012@med.lecom.edu.
- Department of Internal Medicine, Brown University Health Sciences, Providence, RI, USA.
- Department of Hematologic Malignancies and Cellular Therapeutics, Kansas University Medical Center, Kansas City, KS, USA.
Zitieren
APA
Soomro, M. A., Varghese, A., Soomro, H., Abdallah, A. O., Lutfi, F. G., & Ahmed, N. (2026). Masked divergence in cancer mortality following COVID-19 disruption. Cancer Epidemiology, 103, 103133. https://doi.org/10.1016/j.canep.2026.103133
Vancouver
Soomro MA, Varghese A, Soomro H, Abdallah AO, Lutfi FG, Ahmed N. Masked divergence in cancer mortality following COVID-19 disruption. Cancer Epidemiology. 2026;103:103133. doi:10.1016/j.canep.2026.103133
BibTeX
@article{Soomro2026,
author = {Soomro, Mohammad Ahsen and Varghese, Amy and Soomro, Hala and Abdallah, Al-Ola and Lutfi, Forat G and Ahmed, Nausheen},
title = {Masked divergence in cancer mortality following COVID-19 disruption},
journal = {Cancer Epidemiology},
year = {2026},
volume = {103},
pages = {103133},
doi = {10.1016/j.canep.2026.103133}
}
EUVIMED